Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. reports a fifth patient in the Phase 2a ACCENT trial for pancreatic cancer has shown a significant reduction in tumor size, marking a milestone that could soon expand the trial with 24 more patients. The trial investigates narmafotinib, Amplia’s leading drug candidate, in combination with chemotherapy agents, and has revealed promising response rates with six patients also showing stable disease. Amplia remains optimistic about the trial progress, which aims to evaluate the drug’s safety, tolerability, and efficacy in treating advanced pancreatic cancer.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
